Safety Surveillance of COVID-19 vaccines

Member State Briefing 4 March 2021





Presentation objectives

1. Contrast how the safety surveillance of Covid-19 vaccines differs from other vaccines



- 2. Highlight early learnings that can lead to broader improvements to safety surveillance
- 3. Confirm Member State support for safety surveillance efforts



Safety surveillance of Covid-19 vaccines: unique circumstances require innovative approaches

Current context

٠

- Safety surveillance is essential to maintaining positive benefit-risk profile and public confidence in authorized products
- 6 unique circumstances:
 - 1. Unprecedented speed, scale, complexity of rollout
 - 2. Routine detection methods insufficient to manage volume of reports
 - 3. Knowledge gaps (e.g., incomplete data sets)
 - 4. Priority populations including elderly, frail and co-morbidities what is 'fake'/real signal?
 - 5. Ability to link events to specific batches (vaccine, diluent, adjuvant)
 - 6. Intense media and public attention
 - WHO has long played a leadership role in promoting smart safety surveillance practices

Implications


•

- WHO is adopting
 innovative approaches
 to address safety
 issues associated with
 COVID-19 vaccines
 (see next page)
- COVID-19 is serving as a catalyst for broader safety surveillance innovations

From data to decision: the safety process








Key take-aways

- More pro-active
- Enabling real-time data collection and assessment
- Leveraging more data sources (incl. informal sources such as social networks)
- Greater coordination and joint action (e.g., through regulatory networks)
- Ongoing evaluation and adjustment to meet evolving needs

Overview of the COVID-19 vaccine safety ecosystem



Importance of enhanced collaboration to power the system

Examples of collaborations to date

- GAVI: support to facilitate adverse event reporting

lorld Health

- CEPI/SPEAC: list of adverse events of special interest (AESI)
- UNICEF: budgeting for country adverse event surveillance
- Bilaterals: between WHO and EMA

In progress...

CEPI - WHO WG:

- support small developers to meet safety obligations
- improve data flow (developers countries WHO)
 Regulatory networks:
- real-time information exchange
- joint work on emerging safety signals, background rates
- risk management measures and public communications

* Regulators, public health agencies, CDCs

WHO C19 Vaccines safety strategy: *drawing results as designed*

GACVS subcommittee (bi-weekly and ad hoc, as required)

- Reviews emerging 'signals'. Examples include
 - Anaphylaxis: stabilized- input to SAGE
 - Deaths as expected in the age group influential Statement
 - Flu-like reactions as expected statement being prepared

WHO PVG Daily Situation Huddles

- Identifies emerging signals; public concerns; prepare briefings as needed
- Maintains Watch List: hypertension, myocarditis, Bells Palsy...
- Feeds into GACVS subcommittee agenda

WHO Global Database (weekly)

- Weekly review: over 177,000 individual case safety reports (as on 28 Feb)
- Snapshot:
 - 39% of reports in age group 18 44 y; 33% in 45- 64y
 - More events reported in women (75%)







Exposure data and background rates – putting events into context (the "Norway experience")



3

Networks – Earlier detection, better informed decisions and more coordinated response



An agile scientific committee – e.g., GACVS subcommittee and statement on deaths

World Health Organization

WHO welcomes interventions on:

- How Member States could provide political support for the strategy and approach described
- Additional suggestions WHO could consider to address challenges associated with COVID-19 vaccine safety
- Measures Member States are adopting to further strengthen safety surveillance efforts for COVID-19 vaccines



Back-up



Issues/opportunities

- Leverage the HCW cohort to implement active surveillance using LIMC appropriate protocols
- Safety surveillance and risk management plans for non-major markets: the challenges of product developers and countries
- Accessing clinical safety data prior to WHO EUL to inform appropriate safety measures
- Effective use of regulatory reliance: what does it look like?
- What are the greatest opportunities ahead? How can COVID be a driver for permanent change?

WHO safety surveillance strategy for COVID-19 vaccines

Scope	 Addresses all countries and vaccines Inclusive of all stakeholders Routine/active surveillance and specific studies 1st wave rollouts: opportunity to rapidly collect quality data from HCW cohort and apply lessons to subsequent waves
Principles	 Reliance/work-sharing (smart approach) Collaboration with leading regulators/networks Proactive E2E approach (clinical trials to post-introduction) Builds on solid foundation of existing guidance, tools and platforms Catalyst for broader safety surveillance innovations
Elements	 Guidance (data-knowledge-decision) Tools & enablers (to collect, manage adverse event data; protocols; signal review committees; communication networks) Training: (competency based; function-driven)

